AssureCKD Appoints Former LumiraDx Technical Director Dr. Aman Khan as Chief Technology Officer to Lead Diagnostic Platform Development [Yahoo! Finance]
Abbott Laboratories (ABT)
Last abbott laboratories earnings: 4/16 07:30 am
Check Earnings Report
US:NYSE Investor Relations:
abbott.com/investors.html
Company Research
Source: Yahoo! Finance
chronic kidney disease (CKD) screening and diagnosis, today announced the appointment of Dr. Aman Khan as Chief Technology Officer, effective April 13, 2026. Dr. Khan brings more than 30 years of experience in diagnostics and medical technology, with a proven track record of leading platform development from concept through to global commercialization. He is also a prolific innovator, with over 50 issued patents across diagnostic technologies and platform architectures. Most recently, Dr. Khan served as Technical Director at LumiraDx, where he led the development of a next-generation point-of-care diagnostic platform and built global, cross-functional teams across the United Kingdom, United States, and Europe. LumiraDx was subsequently acquired by Roche in a transaction valued at approximately $350 million USD. Prior to LumiraDx, Dr. Khan held senior leadership roles at Alere, a global leader in rapid diagnostics acquired by Abbott Laboratories for approximately $5.8 billion USD
Show less
Read more
Impact Snapshot
Event Time:
ABT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ABT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ABT alerts
High impacting Abbott Laboratories news events
Weekly update
A roundup of the hottest topics
ABT
News
- Here are the major earnings before the open Thursday [Seeking Alpha]Seeking Alpha
- Abbott Verdict And Exact Sciences Deal Reshape Risk And Growth Outlook [Yahoo! Finance]Yahoo! Finance
- Abbott seen posting modest Q1 earnings amid Nutrition segment slowdown [Seeking Alpha]Seeking Alpha
- Abbott Laboratories Insiders Added US$3.10m Of Stock To Their Holdings [Yahoo! Finance]Yahoo! Finance
- ??????? ???????? - ??????????????????2026-2035? [CNET News]CNET News
ABT
Earnings
- 1/22/26 - In-Line
ABT
Sec Filings
- 4/2/26 - Form 4
- 4/2/26 - Form 4
- 4/2/26 - Form 4
- ABT's page on the SEC website